Latest Syndax News & Updates

See the latest news and media coverage for Syndax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Syndax

Commercial-stage oncology company with approved targeted therapies

syndax.com

Headquarters: New York, United States
Company type: Public company
Number of employees: 50–350
Industry: Pharmaceuticals

Last updated Today

Latest news about Syndax

In short: Syndax significantly grew its revenue and expanded its oncology portfolio through key FDA approvals for Revuforj and Niktimvo in 2025-2026.

Company announcements

July 7 Syndax

Syndax highlights late-stage programs and new pipeline assets

The R&D event features SNDX-4321, a novel EGFR inhibitor, and SNDX-62122, a next-generation menin inhibitor, with Phase 2 IPF data expected in 4Q26.

June 11 Syndax

Syndax publishes SAVE data on Revuforj combination in AML

The all-oral regimen showed 88% ORR and 71% CRc in relapsed/refractory AML.

June 11 Syndax

Syndax highlights Revuforj clinical data at EHA 2026

Data show high response rates in multiple acute leukemia subtypes and settings, including real-world and frontline combinations.

June 4 Syndax

Syndax announces $250M private placement of convertible senior notes

The 2.25% notes mature in 2031, and net proceeds of ~$243M will fund R&D, commercialization, and business development.

Media coverage

July 28 Yahoo Finance

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results ...

July 14 Yahoo Finance

Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs - - SNDX-62122, a next-generation...

July 10 Nasdaq

Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

WALTHAM, Mass., July 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

June 11 Yahoo Finance

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib...

Never miss news about Syndax

Track Syndax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Syndax competitors & trending companies

Browse news for competitors to Syndax and other trending companies.